Inventor · disambiguated record
Katy Rezvani
Also filed as: REZVANI KATY
8 granted patents·44 pending applications·4 citations·filing 2016–2025
76Inventor score
Files withUNIV TEXAS52
Top patents by PatentIndex Score
52 records- 0184US11344578B2Immune cells expressing engineered antigen receptorsUNIV TEXAS·Filed 2018·Granted May 31, 2022·2 cites·25 claims
- 0275US12403093B2Methods for production of MSC-derived exosomesUNIV TEXAS·Filed 2023·Granted Sep 2, 2025·0 cites·22 claims
- 0375US12310988B2BCMA chimeric antigen receptors and uses thereofUNIV TEXAS·Filed 2024·Granted May 27, 2025·0 cites·3 claims
- 0475US11766402B2Methods for production of MSC-derived exosomesUNIV TEXAS·Filed 2018·Granted Sep 26, 2023·1 cites·37 claims
- 0568US11154572B2Methods of treatment with natural killer cells matched for killer immunoglobulin receptor typeUNIV TEXAS·Filed 2016·Granted Oct 26, 2021·1 cites·18 claims
- 0665US2022265718A1Immune cells expressing engineered antigen receptorsUNIV TEXAS·Filed 2022·Application pending·0 cites
- 0764US2025312448A1Enhancing the activity of cellular therapies in the tumor microenvironmentUNIV TEXAS·Filed 2023·Application pending·0 cites
- 0862US12473336B2Methods for activation and expansion of natural killer cells and uses thereofUNIV TEXAS·Filed 2019·Granted Nov 18, 2025·0 cites·16 claims
- 0962US12466867B2Methods for activation and expansion of natural killer cells and uses thereofUNIV TEXAS·Filed 2021·Granted Nov 11, 2025·0 cites·10 claims
- 1061US2025228942A1Methods for activation and expansion of engineered natural killer cells and combinations with antibodiesUNIV TEXAS·Filed 2023·Application pending·0 cites
- 1160US2024125765A1A method for selection of cryopreserved cord blood units for the manufacture of engineered natural killer cells with enhanced potency against cancerUNIV TEXAS·Filed 2022·Application pending·0 cites
- 1260US2024336699A1Enhanced chimeric antigen receptors and use thereofUNIV TEXAS·Filed 2024·Application pending·0 cites
- 1359US2025255905A1Bcma chimeric antigen receptors and uses thereofUNIV TEXAS·Filed 2025·Application pending·0 cites
- 1459US2024261332A1Inhibitory chimeric antigen receptor prevents on-target off-tumor effects of adoptive cell therapyUNIV TEXAS·Filed 2022·Application pending·0 cites
- 1558US2024331837A1Selection of viral-specific cytotoxic t-cell lines for the management of viral infectionsUNIV TEXAS·Filed 2022·Application pending·0 cites
- 1657US2025249098A1Cryopreservation of nk cell products for off-the-shelf immunotherapyUNIV TEXAS·Filed 2023·Application pending·0 cites
- 1755US2024382593A1Antibody loaded immune cells and methods for use in cancer treatmentUNIV TEXAS·Filed 2022·Application pending·0 cites
- 1855US2021253729A1Enhanced chimeric antigen receptors and use thereofUNIV TEXAS·Filed 2021·Application pending·0 cites
- 1955US2022409663A1Engineered t cells and tumor-infiltrating lymphocytes to overcome immunosuppression in the tumor microenvironmentUNIV TEXAS·Filed 2020·Application pending·0 cites
- 2054US2025074950A1Methods for production of therapeutic immune cells having enhanced metabolic fitness and compositions thereofUNIV TEXAS·Filed 2022·Application pending·0 cites
- 2154US2024408203A1Engineering nk cells with a car construct with optimal signalingUNIV TEXAS·Filed 2022·Application pending·0 cites
- 2254US2024252539A1Chimeric antigen receptor to target hla-g-positive cancersUNIV TEXAS·Filed 2022·Application pending·0 cites
- 2353US2024325444A1Chimeric antigen receptor to target trop-2-positive cancersUNIV TEXAS·Filed 2022·Application pending·0 cites
- 2453US2024269285A1Polypeptides targeting cd70-positive cancersUNIV TEXAS·Filed 2022·Application pending·0 cites
- 2553US2024189357A1Chimeric antigen receptors to target cd5-positive cancersUNIV TEXAS·Filed 2022·Application pending·0 cites
- 2653US2023220351A1Large-scale production of exosomes from primed mesenchymal stromal cells for clinical useUNIV TEXAS·Filed 2021·Application pending·0 cites
- 2752US2024165162A1Methods for activation and expansion of natural killer cells and combinations with bispecific antibodiesUNIV TEXAS·Filed 2022·Application pending·0 cites
- 2852US2023074303A1Cell immunotherapy for the treatment of cancerUNIV TEXAS·Filed 2021·Application pending·0 cites
- 2952US2023159618A1Enhanced chimeric antigen receptors and use thereofUNIV TEXAS·Filed 2018·Application pending·0 cites
- 3052US2024245614A1Production of therapeutic mesenchymal stem cell-derived exosomesUNIV TEXAS·Filed 2022·Application pending·0 cites
- 3152US2025281612A1Cd27-extracellular domain car to target cd70-positive tumorsUNIV TEXAS·Filed 2022·Application pending·0 cites
- 3252US2024325443A1Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapyUNIV TEXAS·Filed 2022·Application pending·0 cites
- 3351US2022033778A1Methods for ex vivo expansion of natural killer cells and use thereofUNIV TEXAS·Filed 2019·Application pending·0 cites
- 3451US2022033848A1A modular, polycistronic vector for car and tcr transductionUNIV TEXAS·Filed 2019·Application pending·0 cites
- 3551US2022023343A1Suicide geneUNIV TEXAS·Filed 2019·Application pending·0 cites
- 3650US2023040477A1T-cell death associated gene 8 (tdag8) modulation to enhance cellular cancer therapiesUNIV TEXAS·Filed 2021·Application pending·0 cites
- 3750US2023060351A1A method of engineering natural killer cells to target cd70-positive tumorsUNIV TEXAS·Filed 2021·Application pending·0 cites
- 3849US2022378739A1Natural killer cell immunotherapy for the treatment of glioblastoma and other cancersUNIV TEXAS·Filed 2020·Application pending·0 cites
- 3948US2022370500A1A method of engineering natural killer-cells to target bcma-positive tumorsUNIV TEXAS·Filed 2020·Application pending·0 cites
- 4048US2023210902A1Sars-cov-2-specific t cellsUNIV TEXAS·Filed 2021·Application pending·0 cites
- 4148US2023383257A1Production of megakaryocytes and platelets in a co-culture systemUNIV TEXAS·Filed 2021·Application pending·0 cites
- 4247US2022325245A1Methods for production of car-nk cells and use thereofUNIV TEXAS·Filed 2020·Application pending·0 cites
- 4346US2022389383A1Large-scale combined car transduction and crispr gene editing of nk cellsUNIV TEXAS·Filed 2020·Application pending·0 cites
- 4446US2022401479A1Large-scale combined car transduction and crispr gene editing of t cellsUNIV TEXAS·Filed 2020·Application pending·0 cites
- 4546US2022403418A1Large-scale combined car transduction and crispr gene editing of b cellsUNIV TEXAS·Filed 2020·Application pending·0 cites
- 4645US2022288121A1Cell cryopreservation mediumUNIV TEXAS·Filed 2020·Application pending·0 cites
- 4744US2021230548A1Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockadeUNIV TEXAS·Filed 2019·Application pending·0 cites
- 4844US2023045174A1Large-scale combined car transduction and crispr gene editing of msc cellsUNIV TEXAS·Filed 2020·Application pending·0 cites
- 4943US10821134B2BK virus specific T cellsUNIV TEXAS·Filed 2018·Granted Nov 3, 2020·0 cites·21 claims
- 5043US2020390815A1Universal antigen presenting cells and uses thereofUNIV TEXAS·Filed 2019·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Katy Rezvani files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →